About Resolvyx
Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.
Initially funded in 2005, Resolvyx is the first and only company dedicated to the development of new medicines from its Resolvin platform. Pre-clinical research demonstrates that Resolvins have significant potential to treat auto-immune diseases (like crohn's disease, rheumatoid arthritis and psorisasis), allergic diseases (like asthma) and chronic inflammatory diseases (like atherosclerosis, degenerative retinal diseases and chronic dry eye).
With our experienced management team, world-class scientists and leading investors, we are well-positioned to translate our proprietary Resolvin platform into an important new class of pharmaceuticals.